Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pink to go with that "hard" hat (grin)
Sorry couldn't resist poking at this one more time.
LOL. OK.
"No they are not, they are completely separate corporate entities."
No kidding but what was posted was correct. Corporations can have other corporations (subsidiaries) under their corporate umbrella.
So in essence they are the same company. The only thing we don't know for sure is which one is the parent company. IMO it is Aquagold International. But for our purposes here it really doesn't matter because the revenue stream still goes to the top and its all one and the same.
Good Job Sid!
By being subsidiary of Aquagold International IMO.
Nice catch Penny.
Still holding strong here as well. No lack of patience so will wait as long as it takes.
Finally getting closer to .03. I'm hoping for a strong close.
Thanks Leigh
I expected a bit more buying after this news today. I thought the news was pretty good and I still think there is more news in the pipes.
Oh well, there loss hehe
Nice.....
Pretty good timing on this news....lol.
I feel like this is just the beginning.
Good luck to all.
FWIW. ONCO News out this morning.
Oncology Med's Three Year Contract to Treat Prostate Cancer for Affiliate of Largest Health Care System in Ohio on Track to Exceed Financial Goals
Oncology Med Projecting $400,000.00 of Increased Revenue From Contract and Has Treated 15 Patients During the First Two Months of the Contract
Jan 23, 2008 9:00:00 AM
View Additional ProfilesPITTSBURGH, PA -- (MARKET WIRE) -- 01/23/08 -- Oncology Med, Inc. (PINKSHEETS: ONCO) a Pittsburgh based cancer treatment solutions group, announced today that it is on track to exceed its financial projection for its new multiple year exclusive contract with Humility of Mary Health Partners, a division of Catholic Healthcare Partners, the largest health system in Ohio and the seventh largest not-for-profit health system in the United States. During the first two months of this contract, Oncology Med has fifteen patients under treatment with four having completed the full course of treatments.
This exclusive multi-year contract will have Oncology Med providing physics and full turnkey prostate cancer brachytherapy services, equipment, staff, and radionuclide seed management to the system's hospitals of St. Elizabeth Medical Center, St. Elizabeth Boardman Medical Center, and St. Joseph's Medical Center, all of which are located in the greater Youngstown, Ohio area.
According to William Walker, Ph.D., Oncology Med's CEO and founder, "The early financial success of our turnkey prostate treatment program has proven the viability of the Oncology Med model. At the current rate of new patient growth, we can anticipate gross revenues from this contract to exceed earlier projections and is expected to approach $400,000.00 this year. This is a 25% increase over the projected revenues expected at the time the contract was awarded to our company. We are committed to expand our client base by entering into similar contracts with a variety of healthcare organizations, resulting in additional revenue increases."
Jack Sloan, Vice President of Business Development, added, "While only in the early months of this program, the high number of patients being treated under our program is an early indication that many patients are indeed choosing radiation therapy as their treatment of choice for prostate cancer as has been indicated by several studies. Our turnkey brachytherapy program gave the hospital the ability to concentrate on the patients and physicians associated with the treatment of prostate cancer and kept it from having to worry and devote time to the many moving parts of implementing a new brachytherapy seed radiation program from beginning to end. Due to our expertise and clinical experience in this area, Oncology Med had the hospital's brachytherapy seed program in place inside of thirty (30) days, which allowed the physicians to immediately begin referring patients to the treatment at their local hospital," Sloan continued.
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation treatments to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
More information about Oncology Med, Inc. can be found at www.oncologymed.com.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.
For information, please contact:
Mr. Trevor Bentley
Investor Communications
Bentley Communications
1-888-818-8738
Email Contact
ONCO News
Oncology Med's Three Year Contract to Treat Prostate Cancer for Affiliate of Largest Health Care System in Ohio on Track to Exceed Financial Goals
Oncology Med Projecting $400,000.00 of Increased Revenue From Contract and Has Treated 15 Patients During the First Two Months of the Contract
Jan 23, 2008 9:00:00 AM
View Additional ProfilesPITTSBURGH, PA -- (MARKET WIRE) -- 01/23/08 -- Oncology Med, Inc. (PINKSHEETS: ONCO) a Pittsburgh based cancer treatment solutions group, announced today that it is on track to exceed its financial projection for its new multiple year exclusive contract with Humility of Mary Health Partners, a division of Catholic Healthcare Partners, the largest health system in Ohio and the seventh largest not-for-profit health system in the United States. During the first two months of this contract, Oncology Med has fifteen patients under treatment with four having completed the full course of treatments.
This exclusive multi-year contract will have Oncology Med providing physics and full turnkey prostate cancer brachytherapy services, equipment, staff, and radionuclide seed management to the system's hospitals of St. Elizabeth Medical Center, St. Elizabeth Boardman Medical Center, and St. Joseph's Medical Center, all of which are located in the greater Youngstown, Ohio area.
According to William Walker, Ph.D., Oncology Med's CEO and founder, "The early financial success of our turnkey prostate treatment program has proven the viability of the Oncology Med model. At the current rate of new patient growth, we can anticipate gross revenues from this contract to exceed earlier projections and is expected to approach $400,000.00 this year. This is a 25% increase over the projected revenues expected at the time the contract was awarded to our company. We are committed to expand our client base by entering into similar contracts with a variety of healthcare organizations, resulting in additional revenue increases."
Jack Sloan, Vice President of Business Development, added, "While only in the early months of this program, the high number of patients being treated under our program is an early indication that many patients are indeed choosing radiation therapy as their treatment of choice for prostate cancer as has been indicated by several studies. Our turnkey brachytherapy program gave the hospital the ability to concentrate on the patients and physicians associated with the treatment of prostate cancer and kept it from having to worry and devote time to the many moving parts of implementing a new brachytherapy seed radiation program from beginning to end. Due to our expertise and clinical experience in this area, Oncology Med had the hospital's brachytherapy seed program in place inside of thirty (30) days, which allowed the physicians to immediately begin referring patients to the treatment at their local hospital," Sloan continued.
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation treatments to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
More information about Oncology Med, Inc. can be found at www.oncologymed.com.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.
For information, please contact:
Mr. Trevor Bentley
Investor Communications
Bentley Communications
1-888-818-8738
Email Contact
Could you please annotate a chart for ONCO.
Thanks
How long of a play to you figure ONCO is? TIA
"we salute you!"
Picked up some ONCO at .03 so lets see what happens here.
yepper
LOL, your preaching to the choir my friend. Patience is a virtue but it is so damn hard to keep...lol.
c7 never doubted.
I have kind of felt like Jesse is the one who put the gag order into the merger agreement. If you follow his other shell play, they are having an investors meeting and vote on January 21st and I felt like he wanted the lid kept on Aquagold until this meeting date. Possible hoping profits would find their way into this other shell play.
I know this is really a stretch but if news starts coming out on the 21st then maybe I am right.
Doesn't matter now...lol....real soon is finally here.
I think we will all know soon enough with Aquagold finally willing to do a text interview next week.
I have talked to them quite a few times and they have been very "silent" and only willing to say they are still under a black out but we will be very happy soon. They never vary from this.
Now they are willing to lift the curtain next week and finally talk.
When I called Nasdaq they said they were very backed up (like all gov't agencies seem to be). But they told me if the paperwork was hand delivered to them for name and cusip change and R/M completion, it would speed up the process significantly.
So I feel like the logical place for them to hand deliver the paperwork was to the Nasdaq since Nevada can be overnighted and expidited with a small fee.
Of course I seem to be the only one here who thinks this....lol.
Doesn't matter, all will be righted starting tomorrow imo.
Nasdaq filing would be in Maryland. At least that is where the offices were when I called with questions.
I still believe the trip to the states was to Maryland and not Nevada. Nasdaq filing would take longer since we know they can pay a small fee to expidite Nevada. I always felt like they would go to Maryland and then overnight the Nevada paperwork. JMHO BWTFDIK.
Oh well, either way we will finally see name change next week (I hope) and more importantly the long awaitied updates..
Yes it is a good starting point. And if they are willing to do the interviews then they should be willing to start the massive news releases and updates.
Next week is going to be sweet!
No more speculation, just lots of growing profits.
AMEX or bust baby!
LOL golfndude
How is he going to look left if he is looking up to talk to you....lol
LOL, the look on the wizards face when he sees fly show up with ruby red slippers and a pink hard (hat) on. Sorry buddy, couldn't resist poking more fun at your typo....lmao.
(Notice I inserted the missing word to keep it clean....hehe)
to funny..oops is right...hehe
LMAO, proof read your posts fly...a pink hard on might get you in to see the witches monkeys....hehe
Something tells me nobody is going to notice the feather...hehe
Van, the CEO is going to drop a load when he comes to pick you up and there is a half a dozen (or more) investors from IHub there with you...lmao.
Better tell him to drive a bus to pick you up.
You know this means exercise great caution until 2/15 when dealing in the pinks. I bet we will see tons of companies diluting shares up until deadline.
But great news for us penny players after the 15th.
americano
From EDS interview;
EDS : What is your current share structure, Authorized, Outstanding & Public Float? Also can give us an idea what the tradable float might be?
ONMC:
Authorized: 1 Billion
Issued and Outstanding: 716 Million
144 Restricted Control Block: 500 Million
Public Float: 216 Million
sorry, no arguement with that. Just trying to keep everyones "eye on the prize" without building false hopes.
At the risk of looking like the board procrastinator (probably to late now) but EDS was NOT responsible for the run to .185 so don't get to excited over tonights update. Next weeks interview might give us a boost but not tonights email alert...IMHO
The run to .185 came from over a dozen tout services picking us up and blasting us out to their subscribers. Sorry but I don't want anyone getting their expectations up over tonights EDS update. I would think most of EDS subscribers are already onboard and those on the fence will wait for symbol change.
But what the flip do I know!
LOL
LOL, this is such a non-issue. Can't believe everyone is getting so freaking defensive about this.
As I read the last PR, the reason for the delay (and the reason for the latest PR) was because they hadn't gotten all the signatures when they put out the 12/7 news.
I never said they don't have all the signatures now...lol. Last PR confirmed they now have them all.
Geesh, fiesty room today.
Yes the name would have to be change in Nevada since ONMC is a Nevada Corporation. It also has to be changed with Nasdaq.
Since PR said they were personally coming here to file the paperwork to get the name and cusip changed, this is why I believe they went to Maryland. Since we now know the Nevada process can be sped up for a fee, it just makes sense to me that they would go to Maryland to speed up that process.
Again, it is anyones guess where they went. Company won't disclose this (trust me, I tried very hard to get their destination out of them). But the trip to Maryland makes more sense to me.
Aquagold has been great about returning calls. Usually it is one of the BOD guys who call back. This alone she reassure everyone that this is the real deal.
I still think the blackout period ends around the 21st.
JMHO BWTFDIK